Literature DB >> 21045174

Relationships between hepatic stearoyl-CoA desaturase-1 activity and mRNA expression with liver fat content in humans.

Andreas Peter1, Alexander Cegan, Silvia Wagner, Michaela Elcnerova, Alfred Königsrainer, Ingmar Königsrainer, Hans-Ulrich Häring, Erwin D Schleicher, Norbert Stefan.   

Abstract

Stearoyl-CoA desaturase-1 (SCD1) has gained much interest as a future drug target to treat fatty liver and its consequences. However, there are few and inconsistent human data about expression and activity of this important enzyme. We investigated activity and expression of SCD1 and their relationships with liver fat (LF) content in human liver samples. Fifty subjects undergoing liver surgery were studied. SCD1 activity was estimated from the ratio of oleate (C18:1) to stearate (C18:0) within lipid subfractions. Furthermore, SCD1 mRNA expression and LF content were measured. Similarly to previous studies, we observed a strong positive correlation between LF content and the C18:1/C18:0 ratio in the combined fatty acid (FA) fractions (r = 0.96, P < 0.0001), which could be interpreted as higher SCD1 activity with increasing LF. However, hepatic SCD1 mRNA expression did not correlate with LF (r = 0.16, P = 0.13). To solve these conflicting data, we analyzed the FA composition of hepatic lipid subfractions. With increasing LF content the amount of FAs from the triglyceride (TG) fraction increased (r = 0.96, P < 0.0001), whereas the FAs from the phospholipid (PL) fraction remained unchanged (r = -0.17, P = 0.19). Of these two major lipid fractions, the C18:1/C18:0 ratio in TG was 16-fold higher than in PL. Supporting the SCD1 mRNA expression data, the C18:1/C18:0 ratio of the TG or PL fraction did not correlate with LF (r = 0.26, P = 0.12 and r = 0.08, P = 0.29). We provide novel information that SCD1 activity and mRNA expression appear not to be elevated in subjects with high LF content. We suggest that the FA composition of lipid subclasses, rather than of mixed lipids, should be analyzed to estimate SCD1 activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21045174     DOI: 10.1152/ajpendo.00306.2010

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  12 in total

1.  Longitudinal associations of serum fatty acid composition with type 2 diabetes risk and markers of insulin secretion and sensitivity in the Finnish Diabetes Prevention Study.

Authors:  Markus J Takkunen; Ursula S Schwab; Vanessa D F de Mello; Johan G Eriksson; Jaana Lindström; Jaakko Tuomilehto; Matti I J Uusitupa
Journal:  Eur J Nutr       Date:  2015-05-01       Impact factor: 5.614

2.  Bromocriptine mesylate improves glucose tolerance and disposal in a high-fat-fed canine model.

Authors:  Mary Courtney Moore; Marta S Smith; Larry L Swift; Anthony H Cincotta; Michael Ezrokhi; Nicholas Cominos; Yahong Zhang; Ben Farmer; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-05-27       Impact factor: 4.310

3.  Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis.

Authors:  Joseph J Lee; Jennifer E Lambert; Yelena Hovhannisyan; Maria A Ramos-Roman; Justin R Trombold; David A Wagner; Elizabeth J Parks
Journal:  Am J Clin Nutr       Date:  2014-11-19       Impact factor: 7.045

4.  Omega-3 fatty acid deficiency augments risperidone-induced hepatic steatosis in rats: positive association with stearoyl-CoA desaturase.

Authors:  Robert K McNamara; I Jack Magrisso; Rylon Hofacer; Ronald Jandacek; Therese Rider; Patrick Tso; Stephen C Benoit
Journal:  Pharmacol Res       Date:  2012-06-29       Impact factor: 7.658

5.  Coordinated defects in hepatic long chain fatty acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primates.

Authors:  Subhash Kamath; Alberto O Chavez; Amalia Gastaldelli; Francesca Casiraghi; Glenn A Halff; Gregory A Abrahamian; Alberto M Davalli; Raul A Bastarrachea; Anthony G Comuzzie; Rodolfo Guardado-Mendoza; Lilia M Jimenez-Ceja; Vicki Mattern; Ana Maria Paez; Andrea Ricotti; Mary E Tejero; Paul B Higgins; Iram Pablo Rodriguez-Sanchez; Devjit Tripathy; Ralph A DeFronzo; Edward J Dick; Gary W Cline; Franco Folli
Journal:  PLoS One       Date:  2011-11-18       Impact factor: 3.240

6.  Suppressive Role of PPARγ-Regulated Endothelial Nitric Oxide Synthase in Adipocyte Lipolysis.

Authors:  Yoko Yamada; Masato Eto; Yuki Ito; Satoru Mochizuki; Bo-Kyung Son; Sumito Ogawa; Katsuya Iijima; Masao Kaneki; Koichi Kozaki; Kenji Toba; Masahiro Akishita; Yasuyoshi Ouchi
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

Review 7.  The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease.

Authors:  J Bernadette Moore; Pippa J Gunn; Barbara A Fielding
Journal:  Nutrients       Date:  2014-12-10       Impact factor: 5.717

8.  Western diet-induced hepatic steatosis and alterations in the liver transcriptome in adult Brown-Norway rats.

Authors:  Michael D Roberts; C Brooks Mobley; Ryan G Toedebush; Alexander J Heese; Conan Zhu; Anna E Krieger; Clayton L Cruthirds; Christopher M Lockwood; John C Hofheins; Charles E Wiedmeyer; Heather J Leidy; Frank W Booth; R Scott Rector
Journal:  BMC Gastroenterol       Date:  2015-10-30       Impact factor: 3.067

Review 9.  Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease.

Authors:  Sabina Paglialunga; Clayton A Dehn
Journal:  Lipids Health Dis       Date:  2016-09-17       Impact factor: 3.876

10.  Heterogeneity of the Stearoyl-CoA desaturase-1 (SCD1) gene and metabolic risk factors in the EPIC-Potsdam study.

Authors:  Maria Arregui; Brian Buijsse; Norbert Stefan; Dolores Corella; Eva Fisher; Romina di Giuseppe; Oscar Coltell; Sven Knüppel; Krasimira Aleksandrova; Hans-Georg Joost; Heiner Boeing; Cornelia Weikert
Journal:  PLoS One       Date:  2012-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.